Claims for Patent: 9,241,906

Summary for Patent: 9,241,906

Title:	Materials and methods for delivering compositions to selected tissues
Abstract:	This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.
Inventor(s):	Freeman; William R. (Del Mar, CA), Sailor; Michael J. (La Jolla, CA), Cheng; Lingyun (San Diego, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	13/887,045
Patent Claims:	1. A method for treating a disease or disorder of the eye comprising injecting into the eye a composition comprising: a silicon-containing material comprising a plurality of pores, wherein the pores contain a drug, further wherein the silicon-containing material is heated in an oxidizing environment at a temperature above 600.degree. C. before the drug is contacted with the silicon-containing material. 2. The method of claim 1, wherein the release of a drug from the composition is monitored by a change in a reflective wavelength. 3. The method of claim 1, wherein the composition comprises a particle. 4. The method of claim 3, wherein the particle has a size of between about 0.1 .mu.m and 100 .mu.m. 5. The method of claim 1, wherein the composition further comprises a polymeric material capping the pores. 6. The method of claim 1, wherein the pores have a free volume of from 50% to 80%. 7. The method of claim 1, wherein the drug is a protein-based drug. 8. The method of claim 1, wherein the protein-based drug formulation comprises ranibizumab or bevacizumab. 9. The method of claim 1, wherein the disease or disorder of the eye is selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic retinopathy, retinovasclar disease, retinal detachment (PVR) and glaucoma. 10. A pulse therapy method for treating a subject, the method comprising: a) identifying a subject having a condition and selecting one or more active ingredients suitable for treating the condition; b) correlating the quantity and type of active ingredients with a pulse therapy dosing profile suitable for treating the condition; c) configuring a device comprising a silicon-containing material comprising a plurality of pores, wherein the pores contain the one or more active ingredients, further wherein the silicon-containing material is heated in an oxidizing environment at a temperature above 600.degree. C. before the one or more active ingredients is contacted with the silicon-containing material, to obtain a device suitable for delivering the dosing profile of b) to the subject; and d) implanting or explanting the device in or on a target tissue associated with the subject. 11. The method of claim 10, wherein the target tissue is ocular tissue. 12. The method of claim 10, wherein the target tissue is associated with joint tissue. 13. A method for treating a disease or disorder of the eye comprising injecting into an eye a multilayer silicon-containing particle of a size between 0.1 .mu.m and 100 .mu.m comprising: a first surface having a plurality of pores of a first tunable size; a second surface having a plurality of pores of a second tunable size; and a drug disposed within the pores on the first and/or second surface, wherein the multilayer silicon-containing particle is heated in an oxidizing environment at a temperature above 600.degree. C. before the drug is contacted with the particle. 14. The method of claim 13, wherein the multilayer silicon-containing particle further comprises a polymer capping the pores on the first side, second side, or surrounding the particle. 15. The method of claim 13, wherein the drug comprises a protein-based drug. 16. The method of claim 13, wherein the protein-based drug formulation comprises ranibizumab or bevacizumab. 17. The method of claim 13, wherein the disease or disorder of the eye is selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic retinopathy, retinovasclar disease, retinal detachment (PVR) and glaucoma.

Details for Patent 9,241,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2025-10-31